Why the study?
Does endothelin receptor antagonism improve lipid profiles and lower PCSK9 in patients with chronic kidney disease?
Does endothelin receptor antagonism improve lipid profiles and lower PCSK9 in patients with chronic kidney disease?
Answers are grounded in this paper and cite their sources.
Endothelin receptor antagonism improves lipid profiles and lowers PCSK9, offering a potentially novel strategy to reduce cardiovascular disease risk in chronic kidney disease.
receptor antagonism offers a potentially novel strategy to reduce cardiovascular disease risk in CKD. Clinical Trial Registration- URL: http://www.clinicaltrials.gov . Unique identifier: NCT00810732.
No takes yet. Share an insight, caveat, or question.
Farrah et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: